Cargando…

Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease

BACKGROUND: Although the FibroTest has been validated as a biomarker to determine the stage of fibrosis in non‐alcoholic fatty liver disease (NAFLD) with results similar to those in chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD), it has not yet been confirmed for the predictio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Munteanu, Mona, Pais, Raluca, Peta, Valentina, Deckmyn, Olivier, Moussalli, Joseph, Ngo, Yen, Rudler, Marika, Lebray, Pascal, Charlotte, Frederic, Thibault, Vincent, Lucidarme, Olivier, Ngo, An, Imbert‐Bismut, Françoise, Housset, Chantal, Thabut, Dominique, Ratziu, Vlad, Poynard, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Prognostic Valuse of Fibrotest in Chronic Liver Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221139/ https://www.ncbi.nlm.nih.gov/pubmed/30334263 http://dx.doi.org/10.1111/apt.14990

Ejemplares similares

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
por: Poynard, Thierry, et al.
Publicado: (2011)

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Ratziu, Vlad, et al.
Publicado: (2006)

An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

Correction: An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

Meta-analyses of FibroTest diagnostic value in chronic liver disease
por: Poynard, Thierry, et al.
Publicado: (2007)

Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
por: Poynard, Thierry, et al.
Publicado: (2010)

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C
por: Poynard, Thierry, et al.
Publicado: (2004)

LCR1 and LCR2, two multi‐analyte blood tests to assess liver cancer risk in patients without or with cirrhosis
por: Poynard, Thierry, et al.
Publicado: (2018)

Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest)
por: Munteanu, Mona, et al.
Publicado: (2004)

Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes
por: Poynard, Thierry, et al.
Publicado: (2019)

Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia
por: Poynard, Thierry, et al.
Publicado: (2023)

Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis
por: Rudler, Marika, et al.
Publicado: (2015)

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
por: Munteanu, M., et al.
Publicado: (2016)

A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease
por: Halfon, Philippe, et al.
Publicado: (2002)

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity
por: Poynard, Thierry, et al.
Publicado: (2015)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
por: Friedrich-Rust, Mireen, et al.
Publicado: (2010)

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19
por: Deckmyn, Olivier, et al.
Publicado: (2022)

FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis
por: Vali, Yasaman, et al.
Publicado: (2021)

Assessment of Liver Fibrosis: Noninvasive Means
por: Poynard, Thierry, et al.
Publicado: (2008)

The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis
por: Poynard, Thierry, et al.
Publicado: (2019)

Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison
por: Poynard, Thierry, et al.
Publicado: (2016)

Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B
por: Park, Mi Sung, et al.
Publicado: (2013)

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
por: Poynard, Thierry, et al.
Publicado: (2006)

Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery
por: Peta, Valentina, et al.
Publicado: (2017)

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
por: Poynard, Thierry, et al.
Publicado: (2020)

Hirsch Index and Truth Survival in Clinical Research
por: Poynard, Thierry, et al.
Publicado: (2010)

Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers
por: Poynard, Thierry, et al.
Publicado: (2008)

Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data
por: Poynard, Thierry, et al.
Publicado: (2012)

Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B
por: Kim, Beom Kyung, et al.
Publicado: (2012)

The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma
por: Harbour, J. William, et al.
Publicado: (2013)

Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection
por: Maisonnasse, Pauline, et al.
Publicado: (2022)

Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B
por: Poynard, Thierry, et al.
Publicado: (2011)

External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV
por: Poynard, Thierry, et al.
Publicado: (2021)

Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B
por: Kim, Beom Kyung, et al.
Publicado: (2012)

Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience
por: Yakoob, Rafie, et al.
Publicado: (2015)

Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus
por: Bril, Fernando, et al.
Publicado: (2019)

Impact of steatosis and inflammation definitions on the performance of NASH tests
por: Poynard, Thierry, et al.
Publicado: (2018)

Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest – comparison with histopathological assessment
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2017)

Real Time Identification of Drug-Induced Liver Injury (DILI) through Daily Screening of ALT Results: A Prospective Pilot Cohort Study
por: M'Kada, Helmi, et al.
Publicado: (2012)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rgl2bdla5tjie67o1ps8ho7r3p